Pay in 4 interest-free payments of $5.35 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
AOD9604 (Advanced Obesity Drug) was developed by Professor Frank Ng at Monash University in Australia in the 1990s, with the intent of finding an anti-obesity drug that had the fat-burning effects of human growth hormone
5-Amino-1MQ is already reconstituted with MCT oil
The Centers for Disease Control and Prevention (CDC) reports that approximately 3% of adults over age 50 will develop a serious B12 deficiency that can impair health
From available case reports, compounding pharmacy data, and practitioner experience, the following have been observed: BPC-157 Reported Side Effects Nausea and gastrointestinal discomfort (especially with oral administration) Dizziness or light-headedness Flushing or warmth at injection sites Headache Fatigue or somnolence in some users TB-500 Reported Side Effects Injection site reactions (redness, mild pain, swelling) Transient fatigue or lethargy following administration Headache Possible flu-like symptoms in a minority of users Long-Term Risks: What We Don't Know This is arguably the most vital part of this guide
Specifically, it consists of amino acids 176-191 from the growth hormone molecule, plus an additional tyrosine residue at the N-terminus
Cycling: on and off The documented cycling framework runs a continuous 812 week on block (loading through into maintenance) followed by a 48 week off period
